Niacin for primary and secondary prevention of cardiovascular events
Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane meta-analysis of 23 randomised trials with 39,195 participants comparing niacin with placebo or usual care.
Key Findings
Niacin did not reduce all-cause mortality, cardiovascular mortality, myocardial infarction or stroke, and 18% of participants discontinued due to side effects.
Conclusions
Niacin has no clinically meaningful benefit for cardiovascular prevention and causes frequent adverse effects.
Limitations
Trials predominantly in statin-treated secondary prevention populations.
Supplements Studied
Niacin did not reduce all-cause mortality, cardiovascular mortality, myocardial infarction or stroke.
Outcomes Measured
Despite favourable lipid changes, niacin did not reduce cardiovascular events.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.